Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

To view the current issue online, please click here.

Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

<table>
<thead>
<tr>
<th>Bone Marrow Transplant</th>
<th>Gynecologic</th>
<th>Immunotherapy</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Head &amp; Neck</td>
<td>Melanoma/Skin</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Hematology</td>
<td>Neuro-Oncology</td>
<td>Thoracic</td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bone Marrow Clinical Trials**

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**BONE MARROW TRANSPLANT**

**STUDY 2015-115**
Phase II
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

**STUDY 2014-103**
Phase I/II
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

**STUDY BMTCTN1506**
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.
### STUDY 2017-081
**Phase III**
A Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma

### STUDY 2017-072
**Phase III**
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

### STUDY 2016-194
**Phase III**
A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

### STUDY 2016-049
**Phase I/II**
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

### STUDY 2011-086
**NA**
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

### IMMUNOTHERAPY
### STUDY 2018-008
**Phase III**
A Phase 3, Randomized, Open-Label Study of Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

---

### Breast Clinical Trials

For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

### ADJUVANT
### STUDY B-55
**Phase III**
B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo- Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

### STUDY A011202
**Phase III**
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

### STUDY NRG-BR003
**Phase III**
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

### STUDY A011502
**Phase III**
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT HORMONAL
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT RADIATION
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

NEoadjuvant
STUDY RTOG1304
Phase III
NSABP B-51 RTOG1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

STUDY S1418
Phase III
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

STUDY EA1131
Phase III
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neo-adjuvant Chemotherapy.

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADVANCED (STAGE IV) CHEMOTHERAPY
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety and Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY NEW 2018-054
Phase I
<table>
<thead>
<tr>
<th>Study Identification</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-034</td>
<td>Phase I</td>
<td>A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2016-055</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY 2016-116</td>
<td>Phase II</td>
<td>A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY S1501</td>
<td>Phase III</td>
<td>Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III</td>
</tr>
<tr>
<td>STUDY 2017-073</td>
<td>Phase II</td>
<td>The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with Early Stage Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2016-189</td>
<td>Phase I</td>
<td>A Phase I, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY A011401</td>
<td>Phase III</td>
<td>Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2017-029</td>
<td>Phase I</td>
<td>An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours</td>
</tr>
<tr>
<td>STUDY 2017-018</td>
<td>Phase I</td>
<td>A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer</td>
</tr>
<tr>
<td>STUDY EAY131</td>
<td>Phase II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>STUDY 2018-006</td>
<td>NA</td>
<td>Educational Interventions to Promote Tobacco Cessation Among Women Seeking Mammography Screening</td>
</tr>
<tr>
<td>STUDY NEW 2018-062</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

A Phase 1a/1b Study of FPA150, and Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors
Reducing Metabolic Syndrome and Unmet needs Among Rural Breast Cancer Survivors During the Survivorship Transition

**STUDY 2018-015**  
**Phase I/II**  
A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

**STUDY 2016-037**  
**Phase I**  
A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

---

**Gastrointestinal Clinical Trials**

For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**GASTRIC AND GASTROESOPHAGEAL JUNCTION**  
**Metastatic**

**STUDY 2016-210**  
**Phase I/II**  
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY 2017-150**  
**Phase I/II**  
A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

**STUDY 2017-149**  
**Phase I**  
A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer

**STUDY 2017-029**  
**Phase I**  
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

**STUDY 2016-003**  
**Phase I/II**  
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

**STUDY 2016-037**  
**Phase I**  
A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**STUDY 2018-147**  
**Phase II**  
A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Unresectable Gastic or Gastroesophageal Junction (GEJ) Adenocarionoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2
PANCREAS
Adenocarcinoma
Locally Advanced Unresectable
STUDY 2018-048
Phase III
PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and nab-Paclitaxel for Font-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma

Metastatic
STUDY NEW 2018-046
Phase II
A Phase II Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progessed or Recurred after/on First Line Chemotherapy

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-075
Phase I

STUDY 2016-116
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

HCC
Metastatic
STUDY 2016-079
Phase I
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

BILIARY/GALL BLADDER
Metastatic
STUDY 2017-063
Phase II/III
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine versus Placebo Plus Capecitabine in Patients with Advanced or Metastatic Biliary Tract Cancer as Second-Line Systemic Therapy

STUDY NEW 2017-101
Phase I/II
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

COLON
Adjuvant
STUDY A021502
Phase III
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy of Patients with Stage III Colon Cancer with Deficient DNA Mismatch Repair

Metastatic (Includes Rectal)
STUDY NRG-GI004
Phase III
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Metastatic (Includes Rectal)
2nd Line
STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY S1613
Phase II
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

STUDY 2016-185
Phase I/II
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2017-093
Phase II
A Phase 2 Study of MEDI4736 (durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

STUDY 2018-021
Phase II
A Phase 2, Multicenter, Open-Label Study of DS-8201A in Subjects with HER2- Expressing Advanced Colorectal Cancer

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizmab in Subjects with Advanced Solid Tumors

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasability and Utilization of an Application-based Question Prompt List

RECTUM
STUDY 2016-189
Phase I
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasability and Utilization of an Application-based Question Prompt List

STUDY EA2165
Phase II
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

STUDY NRG-GI002
Phase II
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

ANAL
STUDY EA2165
Phase II
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

NEUROENDOCRINE TUMORS AND CARCINOID
STUDY 2017-144
Pilot
Monitoring Telotristat Ethyl Inhibition of Tryptophan hydroxylase (TPH) in Neuroendocrine Tumors Using alpha-[11C]methyl-L-tryptophan (AMT)-PET

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

Genitourinary Clinical Trials
For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

RENA
STUDY S1500
Phase II
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2017-037
Phase II
A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib

STUDY 2018-024
Phase II
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2018-037
Phase II
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

STUDY 2017-058
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

STUDY 2016-201
Phase III
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).

STUDY 2017-111
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2017-083
Phase II
A Single-arm, Multicenter, Phase 2 Study to Evaluate Efficacy and Safety of Lenvatinib in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

STUDY 2016-211
Phase II
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

STUDY 2016-126
Phase II
Phase II Study of Atezolizumab + Bevacizumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

STUDY 2017-036
Phase I
A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Renal Impairment

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY EA8143
Phase III
A Phase 3 Randomized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase/Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-055</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY 2009-139</td>
<td>Phase I</td>
<td>Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer</td>
</tr>
<tr>
<td>STUDY 2014-010</td>
<td>Phase I</td>
<td>A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and other Malignant Solid Tumors that Express Nectin-4</td>
</tr>
<tr>
<td>STUDY NEW 2018-074</td>
<td>Phase II</td>
<td>A Phase 2, Open Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplantin-Ineligible Urothelial Cancer</td>
</tr>
<tr>
<td>STUDY 2018-018</td>
<td>Phase I/II</td>
<td>An Open Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>PROSTATE STUDY 2013-108</td>
<td>NA</td>
<td>Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY NRG-GU002</td>
<td>Phase II/III</td>
<td>Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel</td>
</tr>
<tr>
<td>STUDY 2017-047</td>
<td>Phase II</td>
<td>A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects</td>
</tr>
<tr>
<td>STUDY 2016-153</td>
<td>Phase I</td>
<td>A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer</td>
</tr>
<tr>
<td>STUDY RTOG0924</td>
<td>Phase III</td>
<td>Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial</td>
</tr>
</tbody>
</table>
STUDY 2017-091
Phase II
A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer NCI# 9984

STUDY 2015-135
Phase II
Phase II Trial of Immune Checkpoint Inhibitor with Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.

STUDY 2016-069
Phase II
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)

STUDY 2017-092
Phase II
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2017-051
Phase I
A Phase I Study of PCUR-101 in Combination with Androgen Suppression Therapy in the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

STUDY 2017-046
Phase I
A Phase IB Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Androgen Deprivation Therapy and Other Agents in Subjects with Castrate Resistant Prostate Cancer (CRPC)

STUDY 2017-028
Phase I/II
A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients with Metastatic Castration Resistant Prostate Cancer (CRPC)

STUDY 2015-029
Phase II
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy

STUDY 2017-098
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

STUDY 2017-065
Phase II
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors
**STUDY 2017-156**  
**Phase II**  
A Phase II Open-Label, a Multisite Study of Apalutamide, Abiraterone and Prednisone in African American and Caucasian Men with Metastatic Castrate Resistant Prostate Cancer

**STUDY NRG-GU005**  
**Phase III**  
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

**STUDY 2017-129**  
**NA**  
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

**BLADDER**  
**STUDY 2016-055**  
**Phase I**  
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2017-029**  
**Phase I**  
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

**STUDY 2017-070**  
**Phase II**  
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin(BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

**STUDY NEW 2016-195**  
**Phase II**  
Phase II Trial of Concurrent Nivolumab in UroThelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]

**STUDY 2017-092**  
**Phase II**  
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

**STUDY 2016-003**  
**Phase I/II**  
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

**STUDY 2017-075**  
**Phase I**  
A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers

**STUDY 2017-069**  
**Phase I/II**  
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2016-175**  
**Phase II**  
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

**STUDY 2016-157**
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2014-010
Phase I
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and other Malignant Solid Tumors that Express Nectin-4

STUDY NEW 2018-044
Phase II
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY NEW 2017-101
Phase I/II
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2018-023
Phase I/II
An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY 1163877) in Combination with Atezolizumab as First-line Treatment in Cisplatin-Ineligible Patients with FGFR-positive locally advanced or metastatic urothelial carcinoma

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2016-189
Phase I
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

STUDY 2017-076
Phase I/II
A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects who have Relapsed After, or are Refractory to Standard Therapy

RETURN TO TOP

Gynecologic Clinical Trials

For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

CERVIX
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-010</td>
<td>Phase II</td>
<td>A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma</td>
</tr>
<tr>
<td>STUDY 2017-069</td>
<td>Phase I/II</td>
<td>A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</td>
</tr>
<tr>
<td>OVARY STUDY 2017-153</td>
<td>Phase II</td>
<td>A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab</td>
</tr>
<tr>
<td>STUDY 2017-075</td>
<td>Phase I</td>
<td>A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers</td>
</tr>
<tr>
<td>STUDY 2018-043</td>
<td>Phase III</td>
<td>A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer</td>
</tr>
<tr>
<td>STUDY NRG-GY009</td>
<td>Phase II/III</td>
<td>A Randomized, Phase II/III Study of Pegylated Liposomal Doxirubicin and CTEP-Supplied Atezolizumab (IND #134427) Versus Pegylated Liposomal Doxirubicin/Bevacizumab and CTEP Supplied Atezolizumab Versus Pegylated Liposomal Doxirubicin/Bevacizumab in Platinum Resistant Ovarian Cancer</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-204</td>
<td>Phase II</td>
<td>Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy</td>
</tr>
<tr>
<td>STUDY GOG-3015</td>
<td>Phase III</td>
<td>A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</td>
</tr>
<tr>
<td>STUDY NEW 2018-054</td>
<td>Phase I</td>
<td>A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Solid Advanced Tumors</td>
</tr>
<tr>
<td>STUDY 2018-015</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-029</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
</tr>
</tbody>
</table>
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy of BI 754091 In Patients With Advanced Solid Tumors

UTERUS
STUDY GOG-0238
Phase II
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

VULVAR
STUDY GOG-0279
Phase II
A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva

OTHER
STUDY 2017-153
Phase II
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab

STUDY 2016-204
Phase II
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

STUDY GOG-3015
Phase III
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY NEW 2018-054
Phase I
A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

Head & Neck Clinical Trials

For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

STAGES I/II/III
STUDY 2016-093
Phase I/II
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity
of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

**STUDY EA3132**
Phase II
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

**STUDY 2016-133**
Phase II
A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With (131) I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile

**STUDY 2017-042**
Phase I/II
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer

**STUDY 2017-003**
Phase III
A Randomized Phase III Study of Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy versus Chemoradiation Alone in Subjects with Locally Advanced Head and Neck Squamous Cell Carcinoma

**STUDY 2016-165**
Phase III
A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

**STUDY RTOG1008**
Phase II/III
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

**STAGES I - IV**
**STUDY 2016-189**
Phase I
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

**ANY STAGE**
**STUDY 2009-139**
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

**STUDY 2016-212**
Phase II
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

**STUDY 2018-001**
Phase II
A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
STUDY 2017-107
Phase III
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-149
Phase I/II
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

STUDY 2016-017
Phase I/II
A Phase I/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY NEW 2017-101
Phase I/II
A Dose-Finding Pase I Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

STUDY 2016-037
Phase 1
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

RETURN TO TOP

Hematology Clinical Trials
For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

MULTIPLE MYELOMA
STUDY 2015-036
Phase II
A Phase II Study of IRD (Ixzomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixzomib or Lenalidomide for Multiple Myeloma
STUDY 2012-122
Phase I/II
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma

STUDY 2016-120
Phase I
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma

STUDY E1A11
Phase III
Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

STUDY 2014-090
Phase I
A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

STUDY 2016-062
Phase I/II
Phase 1/2 Trial of Idasanutlin in Combination with Ixazomib and Dexamethasone in Patients with 17p Deleted, Relapsed Phase I/II Multiple Myeloma

STUDY 2017-136
Pilot
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients with Relapsed and/or Refractory Multiple Myeloma

STUDY 2015-022
Phase I
A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (ANTIPD-L1 ANTIBODY) Alone or in Combination with an Immunomodulatory Drug and/or Daratumumab in Patients with Multiple Myeloma (Relapsed and Post-Autologous Stem Cell Transplantation)

STUDY 2018-014
Phase I
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

STUDY 2016-086
Phase I
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

STUDY 2017-024
Phase II
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab

STUDY NEW 2018-042
Phase III
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14) Positive Relapsed or Refractory Multiple Myeloma

AMYLOIDOSIS or LIGHT CHAIN DEPOSITION DISEASE
STUDY 2012-086
Phase III
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-200</td>
<td>Phase II</td>
<td>A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis</td>
</tr>
<tr>
<td>STUDY S1702</td>
<td>Phase II</td>
<td>A Randomized Phase 2 Trial of Revlimid/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide followed by Revlimid/ Dexamethasone/Elotuzumab Maintenance as Second-line Therapy for Patients with Relapsed AL Amyloidosis</td>
</tr>
<tr>
<td>STUDY 2017-067</td>
<td>Phase III</td>
<td>A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated Phase II AL Amyloidosis</td>
</tr>
<tr>
<td>STUDY NEW 2016-060</td>
<td>Phase I</td>
<td>Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis</td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Lymphoblastic Leukemia (ALL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY E1910</td>
<td>Phase III</td>
<td>A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults</td>
</tr>
<tr>
<td>STUDY 2017-159</td>
<td>Phase II</td>
<td>A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults with Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients</td>
</tr>
<tr>
<td>Acute Myeloid Leukemia (AML)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY BMCTN1506</td>
<td>Phase III</td>
<td>A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.</td>
</tr>
<tr>
<td>STUDY 2017-159</td>
<td>Phase II</td>
<td>A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults with Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients</td>
</tr>
<tr>
<td>STUDY 2017-119</td>
<td>Phase III</td>
<td>Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects &lt; or = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia</td>
</tr>
<tr>
<td>STUDY 2017-120</td>
<td>Phase III</td>
<td>A Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia</td>
</tr>
<tr>
<td>STUDY 2016-035</td>
<td>Phase I</td>
<td></td>
</tr>
</tbody>
</table>
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

**STUDY 2016-103**  
**Phase I**  
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

**STUDY 2018-027**  
**Phase I/II**  
A Phase I/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy

**Acute Promyelocytic Leukemia (APL)**  
**STUDY AAML 1331**  
**Phase III**  
A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

**Chronic Myeloid Leukemia (CML)**  
**STUDY 2015-128**  
**Phase II**  
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

**LYMPHOMA**  
**Hodgkin's**  
**STUDY 2016-033**  
**Phase II**  
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Hodgkin's Lymphoma

**STUDY 2017-132**  
**Phase II**  
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

**STUDY 2017-100**  
**Phase III**  
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 812)

**STUDY 2018-013**  
**Phase I/II**  
An Open label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K delta/gamma Dual Inhibitor Given in Combination with an anti-PD-1 Therapy, Pembrolizumab in Adult Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma (cHL)

**Non-Hodgkin’s**  
**Aggressive (Mantle Cell, Large B-Cell Lymphoma)**  
**STUDY 2017-025**  
**Phase III**  
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

**STUDY 2017-007**  
**Phase I**
# Clinical Trials Overview

**A Multi-Center, Open label, Dose Escalation, Phase I/Ib Study to Evaluate the Safety and Efficacy of RP4010, a Calcium Release Activated Calcium (CRAC) Channel Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma**

**STUDY 2013-047**  
**Phase I**  
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

**STUDY 2017-125**  
**Phase III**  
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing The Efficacy And Safety Of Polatuzumab Vedotin In Combination With Rituximab And Chp (R-Chp) Versus Rituximab And Chop (R-Chop) In Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

**STUDY 2016-147**  
**Phase II**  
A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

**STUDY 2015-150**  
**Phase I/II**  
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

**STUDY 2018-008**  
**Phase III**  
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

**Indolent**

**STUDY 2017-068**  
**Phase II**  
A Phase 2, Multicenter, Open-Label, Randomized Study of INC050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

**T cell**

**STUDY 2009-139**  
**Phase I**  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

**STUDY 2016-210**  
**Phase I/II**  
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY 2016-056**  
**Phase II**  
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

**STUDY 2018-003**  
**Phase I**  
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma

**STUDY 2017-069**  
**Phase II**
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2017-008**  
**Phase I**  
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas

**STUDY 2016-037**  
**Phase I**  
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**MYELODYSPLASTIC SYNDROME (MDS)**  
**STUDY 2014-037**  
**Phase I**  
A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents

**STUDY 2016-035**  
**Phase I**  
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

**STUDY 2018-027**  
**Phase I/II**  
A Phase I/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naive Patients Not Eligible for Intensive Induction Therapy

**STUDY 2018-068**  
**Phase I/II**  
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)

**MYELOPROLIFERATIVE DISORDERS**  
**STUDY 2017-079**  
**Phase II**  
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

**STUDY 2017-133**  
**Phase I**  
A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the Treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), and Post-Essential Thrombocythemia MF (post-ET MF)

**OTHER**  
**STUDY 2013-113**  
**Phase II**  
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

**STUDY 2017-159**  
**Phase II**  
A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults with Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

**STUDY EAY131**
**Immunotherapy Clinical Trials**

For more information on Immunotherapy Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**IMMUNOTHERAPY**
**STUDY 2018-015**  
Phase I/II  
A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

**Melanoma/Skin Clinical Trials**

For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**ADVANCED**
**STUDY 2015-034**  
Phase I/II  
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

**STUDY 2016-210**  
Phase I/II  
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY 2017-029**  
Phase I  
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumors

**STUDY 2017-127**  
Phase I  
A Phase IB Study Evaluating Cobimetinib Plus Atezolizumab in Patients with Advanced BRAFV600 Wild-Type Melanoma Who Have Progressed During or After Treatment with Anti-PD-1 Therapy and Atezolizumab Monotherapy in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma

**STUDY 2017-069**  
Phase I/II  
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2016-037**  
Phase I  
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
STUDY NEW EA6134
Phase III
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY S1320
Phase II
A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

STUDY 2016-017
Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

OTHER
STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-128
Phase III
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

STUDY 2016-149
Phase I/II
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

RETURN TO TOP

Neuro-Oncology Clinical Trials
There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.
Phase I Clinical Trials

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

ALL SOLID TUMORS

STUDY 2017-111
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2017-122
Phase I
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2018-019
Phase I
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

STUDY 2017-086
Phase I/II
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

STUDY 2016-170
Phase I/II
A Phase I/IIa, Open-Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy

STUDY 2017-084
Phase I
Phase 1b Multi-Indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies

STUDY 2016-189
Phase I
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

STUDY 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2016-185
Phase I/II
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer

STUDY 2017-036
Phase I
A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Renal Impairment

STUDY 2017-037
<table>
<thead>
<tr>
<th>Phase</th>
<th>Study Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II</td>
<td>STUDY 2017-088</td>
<td>A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2016-135</td>
<td>A Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>STUDY 2017-052</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2016-157</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2015-011</td>
<td>A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination with PLX3397 in Patients with Advanced Solid Tumors and Patients with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated with Imatinib Mesylate, Sunitinib Malate, and Regorafenib</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>STUDY 2015-034</td>
<td>A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2016-042</td>
<td>A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone plus Ethinyl Estradiol) in Female Patients with Solid Tumors</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2016-037</td>
<td>A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2009-139</td>
<td>Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>STUDY 2016-075</td>
<td>A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2017-146</td>
<td>A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors</td>
</tr>
<tr>
<td>Phase I</td>
<td>STUDY 2018-066</td>
<td>A Phase I Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)</td>
</tr>
</tbody>
</table>
STUDY 2018-035
Phase I
A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-Tumor Activity of FN-1501 Monotherapy in Patients with Advanced Solid Tumors

STUDY NEW 2018-054
Phase I
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY NEW 2017-101
Phase I/II
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

STUDY 2018-055
Phase I
A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients with Advanced Solid Tumors

TUMOR SPECIFIC
STUDY 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2016-079
Phase I
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2017-037
Phase II
A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib

STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-075
Phase I
A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers

STUDY 2017-018
Phase I
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

STUDY 2015-034
Phase I/II
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-055
Phase I
A Phase 1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

GENOMIC TESTING SPECIFIC
STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY NEW 2018-054
Phase I
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

RETURN TO TOP

Sarcoma Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

RETURN TO TOP

Thoracic Clinical Trials

For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

STAGE I/II
STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY A081105
Phase III
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

STUDY EA5161
Phase II
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

STUDY NEW 2018-074
Phase II
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin- Ineligible Urothelial Cancer

STAGE III A/B
STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY 2017-152
Phase II
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

STUDY S1400
Phase II/III
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2018-060
Phase II
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY NEW 2018-074
Phase II
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin- Ineligible Urothelial Cancer

STAGE IV
ALK
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY NEW 2018-080
Phase II
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
**EGFR**

**STUDY 2017-145**

**Phase II**

A Phase 2 Study of Pzziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

**STUDY 2015-133**

**Phase II**

A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-type (wt), Advanced Nonsmall Cell Lung Cancer (NSCLC)

**Other Genetic Marker**

**STUDY S1400**

**Phase II/III**

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

**STUDY 2017-145**

**Phase II**

A Phase 2 Study of Pzziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

**STUDY 2017-111**

**Phase I**

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

**STUDY 2017-093**

**Phase II**

A Phase 2 Study of MEDI4736 (durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

**STUDY 2016-134**

**Phase II**

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

**STUDY 2016-017**

**Phase I/III**

A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

**STUDY 2009-139**

**Phase I**

Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

**STUDY 2016-055**

**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2014-002**

**Phase II**

A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens

**STUDY 2016-037**

**Phase I**

A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with
STUDY 2018-049
Phase II
A Phase II, Randomized, Blinded, Placebo-Controlled Study of MTIG7192A, an Anti-Tigit Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

STUDY 2018-060
Phase II
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2016-034
Phase I
A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY NEW 2018-074
Phase II
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin-Ineligible Urothelial Cancer

RECURRENT
ALK
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinum-based Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

EGFR
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinum-based Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

Other Genetic Marker
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor,
Administered Orally to Patients with Advanced Cancer

**STUDY 2018-015**  
Phase I/II  
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

**SCLC EXTENSIVE**  
**STUDY 2017-138**  
Phase I/II  
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination with Pembrolizumab in the Treatment of Patients with Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

**SARCOMA**  
**STUDY 2009-139**  
Phase I  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

**OTHER**  
**STUDY 2009-139**  
Phase I  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

**STUDY EAY131**  
Phase II  
Molecular Analysis for Therapy Choice (MATCH)

**STUDY 2016-189**  
Phase I  
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

**STUDY 2016-116**  
Phase II  
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

**STUDY 2017-069**  
Phase I/II  
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2017-029**  
Phase I  
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

RETURN TO TOP
This email was sent to lowed@karmanos.org. To ensure that you continue receiving our emails, please add us to your address book or safe list.

manage your preferences | opt out using TrueRemove®.

Got this as a forward? Sign up to receive our future emails.